The challenge to develop a new BCG immunotherapy against non-muscle invasive bladder cancer
Project/Area Number |
26861274
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Urology
|
Research Institution | Kyushu University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 膀胱癌 / BCG / BCG / 膀胱がん / インターロイキン15 |
Outline of Final Research Achievements |
BCG is used for the treatment of bladder cancer. The recruitment of neutrophlis to the bladder after BCG instillation exerts anti-tumor activity against bladder tumor. We have recently demonstrated that interleukin (IL)-17A produced by gamma-delta (gd) T cells played a role in the recruitment of neutrophlis to the bladder after BCG instillation. We previously constructed a recombinant BCG strain expressing the fusion protein of IL-15 and Ag85B (BCG-IL-15) for prevention of Mycobacterium tuberculosis infection. Here we compared the efficacy of the BCG-IL-15 in protection against bladder cancer with that of rBCG-Ag85B (BCG). BCG-IL-15 treatment significantly prolonged survival of mice inoculated with bladder cancer cells compared with BCG treatment. Infiltration of neutrophils was significantly elevated in BCG-IL-15 treated mice accompanied by increased chemokinesin the bladder. Thus, BCG-IL-15 exerted additive effect on Infiltration of neutrophils in the bladder.
|
Report
(3 results)
Research Products
(3 results)
-
[Journal Article] Equol inhibits prostate cancer growth via degradation of the androgen receptor by Skp2.2016
Author(s)
Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M, Yokomizo A.
-
Journal Title
Cancer Sci
Volume: in press
Pages: 327-331
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-